文献速递淋巴瘤

循环树突状细胞缺陷作为经典霍奇金淋巴瘤的新生物标志物

Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2018-11-13

研究对52例新诊断经典霍奇金淋巴瘤患者用多参数流式细胞术检测血树突状细胞水平,发现各亚群中位数均低于健康对照(P < 0·001),且与分期、B症状等相关,治疗后在26例中显著升高。

要点

  • 经典霍奇金淋巴瘤患者血mDC1、mDC2、pDC中位数均低于健康对照(P < 0·001)。
  • 晚期患者mDC1与mDC2中位数低于早期(P = 0·008;P = 0·0007)。
  • 治疗结束时26例各DC亚群均升高(P < 0·001),与对照参考频率对齐。

核心结论

  • 树突状细胞可能参与经典霍奇金淋巴瘤典型的免疫相互作用紊乱,提示需进一步评估其作为潜在新生物标志物的价值。

研究设计与样本

  • 研究纳入52例新诊断经典霍奇金淋巴瘤患者,采用多参数流式细胞术评估血树突状细胞水平。
  • 除两例外,所有患者接受ABVD方案(多柔比星、博来霉素、长春碱、达卡巴嗪)。

主要发现

  • 经典霍奇金淋巴瘤患者所有树突状细胞亚群中位数均低于健康对照(P < 0·001)。
  • 晚期较早期患者mDC1与mDC2中位数更低(P = 0·008;P = 0·0007)。
  • 有巨大肿块者mDC2中位数降低(P = 0·0004),有结外病变者mDC2中位数降低(P = 0·046)。
  • 有B症状者mDC1(P = 0·046)、mDC2(P = 0·009)和pDC(P = 0·040)水平更低。
  • 26例治疗结束时所有树突状细胞亚群均升高(P < 0·001):mDC1升高4·6倍,mDC2升高2·4倍,pDC升高4·5倍,且树突状细胞亚群与对照的参考频率及四分位距对齐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

No robust biomarkers have been yet validated to identify the recurrence of disease in classical Hodgkin Lymphoma (cHL) patients upon induction treatment. The relevance of the inflammatory microenvironment in cHL prompted us to investigate the key immunomodulator myeloid dendritic cells type-1 (mDC1), type-2 (mDC2) and plasmacytoid dendritic cells (pDC). Blood DC levels were assessed in 52 newly diagnosed patients through multiparametric flow-cytometry. All but two patients received ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine). The median counts of all DC subsets were lower in cHL patients than in healthy controls (P < 0·001). Median mDC counts were inferior for the advanced vs early stage patients for both mDC1s and mDC2s (P = 0·008; P = 0·0007 respectively). Also, median mDC2 counts were reduced in case of bulky (P = 0·0004) and extra-nodal (P = 0·046) disease. Patients with B symptoms had lower levels for mDC1s (P = 0·046), mDC2s (P = 0·009) and pDCs (P = 0·040). All the DC subtypes increased at the end of treatment in 26 patients (P < 0·001): 4·6-fold for mDC1, 2·4-fold for mDC2, 4·5-fold for pDC and aligned DCs subsets with the reference frequencies and the interquartile ranges of the controls. In conclusion, DCs may contribute to the disturbed immunological interplay typical of cHL, prompting a further evaluation of their value as a potential new biomarker.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Galati D, Zanotta S, Corazzelli G, et al. Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma. Br J Haematol. 2018. PMID: 30426471. doi:10.1111/bjh.15676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。